Clinical Core

临床核心

基本信息

  • 批准号:
    10419277
  • 负责人:
  • 金额:
    $ 30.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-07 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

1 ABSTRACT – Clinical Core 2 The Clinical Core of the Stanford HIPC U19 will provide state-of-the-art clinical and biospecimen support for all 3 the research projects, the Immune Monitoring and the Data Management and Analysis Cores, as well as the 4 expertise, facilities, personnel, procedures and processes for the implementation and conduct of the proposed 5 clinical projects. The Clinical Core will provide and update processes and training for clinical investigators and 6 staff; organize, implement, monitor and work to improve clinical project performance; and conduct quality control 7 and corrective action and handle protocol deviations (if needed), including assuring adherence to milestones, 8 project performance expectations, standardized approach in the recruitment and clinical characterization, 9 appropriate human subject protection measures and clinical Good Practice Guidelines. The Clinical Core will 10 provide the clinical research units which include the infrastructure for longitudinal studies: recruitment, retention, 11 data entry and data management, quality review, sample collection (blood, fine needle aspiration (FNA) and 12 bone marrow (BM) aspirates) processing, isolation and cataloging of various specimen types and will oversee 13 all regulatory-related documents and IRB compliant research. The Clinical Core will coordinate clinical 14 biospecimen storage informatics, connecting clinical, biospecimen management, and assay pipelines into a 15 cutting-edge search engine and analysis platform for clinical and translational research. The Clinical Core will 16 be led by Dr. Kari Nadeau with Associate Director Dr. Nadine Rouphael, Dr. Long at UCSF, and Drs. Madhi and 17 Nunez at hospitals in S. Africa. The Clinical Core will work closely with the other cores and projects to enable 18 the functional analysis of any samples with cutting-edge technologies. Drs. Nadeau, Rouphael, Long, Madhi, 19 and Nunez and their teams have the expertise to be able to comprehensively serve as the Clinical Core 20 personnel since they have been successful in other NIH related consortium studies, in performing Clinical Core 21 duties for other immunology clinical studies, and have worked with Drs. Pulendran, Davis, Maecker, Khatri and 22 Boyd for over 15 years. The Core Leader will represent the HIPC center in a HIPC Clinical Sub-Committee that 23 will operate under the HIPC Coordinating Center to promote cross-HIPC collaboration including sharing SOPs, 24 documents, and samples as appropriate. The Clinical Core proposes the following aims: (1) To perform clinical 25 studies with COVID-19 vaccines, and on the impact of the microbiome on rabies vaccination, to provide clinical 26 data and samples to accomplish the scientific goals of the research projects; (2) Establish and maintain 27 personnel training, procedures, and processes to provide core clinical support; and (3) Establish and maintain 28 protocol milestones, performance guidelines, communication strategies, and compliance in clinical studies and 29 sample collection. In summary, the Clinical Core will leverage state-of-the-art biospecimen support services and 30 will coordinate all operational and regulatory aspects of research for the HIPC U19 projects. 31
1摘要-临床核心 2斯坦福大学HIPC U19的临床核心将为所有人提供最先进的临床和生物标本支持。 3研究项目,免疫监测和数据管理和分析核心,以及 4实施和进行拟议的 5临床项目临床中心将为临床研究者提供并更新流程和培训, 6名工作人员;组织、实施、监督和努力提高临床项目绩效;并进行质量控制 纠正措施和处理方案偏离(如需要),包括确保遵守里程碑, 8项目绩效预期、招募和临床特征描述的标准化方法, 9项适当的人类受试者保护措施和临床良好实践指南。临床核心将 10提供临床研究单位,包括纵向研究的基础设施:招募,保留, 11数据录入和数据管理、质量审查、样本采集(血液、细针穿刺(FNA)和 12个骨髓(BM)穿刺)处理,分离和各种标本类型的编目,并将监督 13所有法规相关文件和IRB合规研究。临床核心将协调临床 14个生物样本存储信息,将临床、生物样本管理和分析管道连接到一个 15个用于临床和转化研究的尖端搜索引擎和分析平台。临床核心将 16由Kari Nadeau博士与副主任Nadine Rouphael博士,UCSF的Long博士和Madhi博士领导, 17努涅斯在S.非洲临床核心将与其他核心和项目密切合作, 18.采用尖端技术对任何样品进行功能分析。纳多,鲁菲尔,朗,麦迪医生 19和Nunez及其团队拥有能够全面作为临床核心的专业知识 20名人员,因为他们在其他NIH相关联盟研究中取得了成功, 其他免疫学临床研究的21项职责,并曾与Pulendran,Davis,Maecker,Khatri和 22博伊德超过15年。核心负责人将代表HIPC中心参加HIPC临床分委员会, 23将在重债穷国协调中心下运作,以促进重债穷国之间的合作,包括分享标准作业程序, 24份文件和适当的样本。临床核心提出了以下目标:(1)进行临床 25项关于COVID-19疫苗以及微生物组对狂犬病疫苗接种的影响的研究, 26个数据和样本,以完成研究项目的科学目标;(2)建立和维护 27提供核心临床支持的人员培训、程序和流程;以及(3)建立和维护 临床研究中的28个方案里程碑、性能指南、沟通策略和依从性,以及 29个样本采集。总之,临床核心将利用最先进的生物标本支持服务, 30将协调重债穷国U19项目研究的所有业务和监管方面。 31

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kari C. Nadeau其他文献

Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial
在“口服免疫治疗疗效和安全性评估(POISED)”试验中,基线表位特异性免疫球蛋白E(IgE)谱可预测口服免疫治疗1年后持续无反应或高阈值反应情况。
  • DOI:
    10.1016/j.jaci.2024.10.017
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    11.200
  • 作者:
    Maria Suprun;Ashley Sang Eun Lee;Robert Getts;Simon Peck;Sayantani B. Sindher;Kari C. Nadeau;R. Sharon Chinthrajah;Stephen J. Galli;Hugh A. Sampson
  • 通讯作者:
    Hugh A. Sampson
Identification , Characterization , and initial epitope mapping of a pine nut allergen
松子过敏原的鉴定、表征和初始表位作图
  • DOI:
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Yuzhu Zhang;Wen;Yuting Fan;Jiang Yi;S. Lyu;Kari C. Nadeau;Tara H. McHugh
  • 通讯作者:
    Tara H. McHugh
Novel dosing strategy of omalizumab during multi-allergen oral-immunotherapy
  • DOI:
    10.1016/j.waojou.2020.100415
  • 发表时间:
    2020-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Sayantani B. Sindher;Andrew Long;Natasha Purington;Divya Kumar;Stacey Skura;Margaret A. Woch;Tiffany Tan;Andres Alvarez;R. Sharon Chinthrajah;Maria Garcia-Lloret;Kari C. Nadeau
  • 通讯作者:
    Kari C. Nadeau
How does global warming contribute to disorders originating from an impaired epithelial barrier?
全球变暖如何导致源自上皮屏障受损的疾病?
  • DOI:
    10.1016/j.anai.2023.08.010
  • 发表时间:
    2023-12-01
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Cevdet Ozdemir;Umut Can Kucuksezer;Ismail Ogulur;Yagiz Pat;Duygu Yazici;Ioana Agache;Marek Jutel;Kari C. Nadeau;Mübeccel Akdis;Cezmi A. Akdis
  • 通讯作者:
    Cezmi A. Akdis
Decreased Migratory Potential of Treg Cells in CRSwNP
  • DOI:
    10.1016/j.otohns.2010.06.707
  • 发表时间:
    2010-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Amanda Munoz;Kari C. Nadeau;Peter H. Hwang
  • 通讯作者:
    Peter H. Hwang

Kari C. Nadeau的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kari C. Nadeau', 18)}}的其他基金

Clinical Core
临床核心
  • 批准号:
    10584556
  • 财政年份:
    2022
  • 资助金额:
    $ 30.97万
  • 项目类别:
Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH)
空气污染扰乱心肺总体健康中的炎症小体调节 (AIRHEALTH)
  • 批准号:
    10460326
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Administrative Core for the Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH) Study
空气污染的管理核心扰乱心肺总体健康(AIRHEALTH)研究中的炎症小体调节
  • 批准号:
    10269331
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10491675
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Clinical Core
临床核心
  • 批准号:
    10687221
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Administrative Core for the Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH) Study
空气污染的管理核心扰乱心肺总体健康(AIRHEALTH)研究中的炎症小体调节
  • 批准号:
    10684157
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH)
空气污染扰乱心肺总体健康中的炎症小体调节 (AIRHEALTH)
  • 批准号:
    10684155
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Interaction between genetic, lifestyle and environmental factors determining circulating angiotensin-converting enzyme 2 protein expression: implications for the severity of COVID-19 infection
遗传、生活方式和环境因素之间的相互作用决定循环血管紧张素转换酶 2 蛋白表达:对 COVID-19 感染严重程度的影响
  • 批准号:
    10228516
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Project 1 for the Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH) Study
空气污染扰乱心肺总体健康 (AIRHEALTH) 研究中的炎症小体调节项目 1
  • 批准号:
    10684167
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Project 1 for the Air pollution disrupts Inflammasome Regulation in HEart And Lung Total Health (AIRHEALTH) Study
空气污染扰乱心肺总体健康 (AIRHEALTH) 研究中的炎症小体调节项目 1
  • 批准号:
    10269334
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 30.97万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 30.97万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 30.97万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 30.97万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 30.97万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 30.97万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 30.97万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 30.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了